Abstract
Reserpine depletes dopamine (DA) levels and increases tyrosine hydroxylase (TH) activity in the rat corpus striatum. TH is activated not only by enhancement of DA neuronal impulse flow, but also by cessation of impulse flow. To assist in the understanding of the relative contribution of impulse flow to the regulation of TH activity in the DA depleted neuron, we examined the consequences of severe DA depletion on substantia nigra DA neuronal impulse flow and on in vivo TH activity in the rat corpus striatum. One day after reserpine or 30 min after the reversible reserpine-like compound, Ro4-1284, striatal DA levels were severely depleted and in vivo TH activity was enhanced about three-fold. DA depletion was found to significantly increase DA neuronal impulse flow. Although the DA neuron is firing faster than normal in the DA depleted rat, because there is no DA being released it is still not clear whether the elevation in TH activity is due to the enhancement of impulse flow or to the lack of DA at presynaptic receptor sites, or both. gamma-Butyrolactone (GBL), causes a cessation of DA neuronal impulse flow and activates TH by a presynaptic autoreceptor mechanism. GBL inhibited by over 50 percent the elevation in TH activity pr...Continue Reading
References
Mar 15, 1976·Biochemical Pharmacology·J R Walters, R H Roth
Mar 15, 1976·Biochemical Pharmacology·V H MorgenrothR H Roth
Jan 1, 1979·Journal of Neural Transmission·D C GermanP A Shore
Mar 29, 1977·Naunyn-Schmiedeberg's Archives of Pharmacology·W KehrM Lindqvist
Jan 1, 1976·Journal of Neural Transmission·P A Shore
Jan 1, 1972·Naunyn-Schmiedeberg's Archives of Pharmacology·W KehrM Lindqvist
May 1, 1966·Life Sciences·N H Neff, E Costa
Aug 1, 1980·Naunyn-Schmiedeberg's Archives of Pharmacology·B A McMillen, P A Shore
Citations
Oct 1, 1985·Naunyn-Schmiedeberg's Archives of Pharmacology·O F Jenkins, D M Jackson
Apr 1, 1986·Naunyn-Schmiedeberg's Archives of Pharmacology·K RackéE Muscholl
Jan 11, 1992·Journal of Neural Transmission. General Section·D E Dluzen, F T Kratko
Sep 1, 1994·Psychopharmacology·J L NeisewanderD A Davis
Dec 15, 1989·Biochemical Pharmacology·C T Giambalvo
Dec 25, 1989·Brain Research·C W CallawayD S Segal
Nov 19, 1990·Brain Research·J R Hollerman, A A Grace
Nov 13, 1992·European Journal of Pharmacology·C J SchmidtV L Taylor
Jun 3, 1996·European Journal of Pharmacology·J L NeisewanderA N Sussman
Jun 30, 1986·Life Sciences·C A HamiltonJ L Reid
Jan 1, 1982·Progress in Neurobiology·W Schultz
Oct 1, 1984·Brain Research Bulletin·S Howard-ButcherR F Lane
Feb 13, 1999·European Journal of Pharmacology·S YehudaD I Mostofsky
Mar 3, 1999·The European Journal of Neuroscience·M ScarponiN B Mercuri
Jul 9, 2008·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Irene BrunkGudrun Ahnert-Hilger
Jul 1, 1993·Journal of Neurochemistry·A H Tissari, M S Lillgäls
May 1, 1983·Medical Hypotheses·F E Barr
Jan 14, 1998·Neuron·Y M WangM G Caron
Jan 5, 2013·Experimental Neurology·Joshua M BradnerW Michael Caudle
Sep 11, 1992·Brain Research·J R Hollerman, A A Grace
Sep 21, 1981·Life Sciences·J D MillerD C German
Jan 1, 1988·Neuroscience and Biobehavioral Reviews·L A Chiodo
Aug 18, 2021·Acta Physiologica·Diego BaronioPertti Panula